| 1 |
32194866 | Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria. | 2020 |
3 |
| 2 |
31427687 | Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer. | 2019 Aug 19 |
1 |
| 3 |
29383406 | Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. | 2018 Jul |
1 |
| 4 |
29904592 | Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis. | 2018 |
1 |
| 5 |
27960186 | Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study. | 2017 |
1 |
| 6 |
26975660 | Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. | 2016 Mar 14 |
1 |
| 7 |
27493956 | Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade. | 2016 |
2 |
| 8 |
27793943 | Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer. | 2016 Nov |
3 |
| 9 |
24458472 | Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. | 2014 Mar |
1 |
| 10 |
17445976 | Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. | 2008 Feb |
1 |
| 11 |
17960608 | Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. | 2007 Dec 15 |
1 |
| 12 |
16413696 | Rising prostate-specific antigen values during neoadjuvant androgen deprivation therapy: The importance of monitoring. | 2006 May 1 |
1 |
| 13 |
16765527 | Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation. | 2006 Dec 1 |
1 |